Hepatitis delta and HIV infection

Seminars in Liver Disease

Volumn 32, Issue 2, 2012, Pages 120-129

  Serrano, Beatrizcalle ^a   Manns, Michaelp ^a   Wedemeyer, Heiner ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

coinfection; HBV; HDV; hepatitis B virus; hepatitis delta virus; HIV; multiple hepatitis infections

Indexed keywords

ADEFOVIR; ANTIRETROVIRUS AGENT; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FAMCICLOVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS DELTA ANTIGEN; LAMIVUDINE; LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; PEGINTERFERON ALPHA; RIBAVIRIN; VIRUS RNA;

ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; DECOMPENSATED LIVER CIRRHOSIS; DELTA AGENT HEPATITIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TOLERABILITY; ELASTOGRAPHY; ENDOSCOPY; FULMINANT HEPATIC FAILURE; GENOTYPING TECHNIQUE; HEPATITIS B; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TOXICITY; LIVER TRANSPLANTATION; MALE HOMOSEXUAL; MIXED INFECTION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; VIRAL CLEARANCE; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS LOAD; VIRUS REPLICATION;

ANTIVIRAL AGENTS; COINFECTION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS D; HEPATITIS DELTA VIRUS; HIV; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; LIVER; LIVER CIRRHOSIS;

EID: 84863224162     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0032-1316467     Document Type: Article

References (98)

1. Rizzetto M. Hepatitis D: thirty years after. J Hepatol: 2009; 50 5 1043 1050
2. Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol: 2010; 7 1 31 40
3. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet: 2011; 378 9785 73 85
4. Rizzetto M, Hoyer B, Canese MG, Shih JW, Purcell RH, Gerin JL. delta Agent: association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees. Proc Natl Acad Sci U S A: 1980; 77 10 6124 6128
5. Ponzetto A, Hoyer BH, Popper H, Engle R, Purcell RH, Gerin JL. Titration of the infectivity of hepatitis D virus in chimpanzees. J Infect Dis: 1987; 155 1 72 78
6. Rosenblum L, Darrow W, Witte J., et al. Sexual practices in the transmission of hepatitis B virus and prevalence of hepatitis delta virus infection in female prostitutes in the United States. JAMA: 1992; 267 18 2477 2481
7. Wu JC, Chen CM, Sheen IJ, Lee SD, Tzeng HM, Choo KB. Evidence of transmission of hepatitis D virus to spouses from sequence analysis of the viral genome. Hepatology: 1995; 22 6 1656 1660
8. Kucirka LM, Farzadegan H, Feld JJ., et al. Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users. J Infect Dis: 2010; 202 6 845 852
9. Arribas JR, González-García JJ, Lorenzo A., et al. Single (B or C), dual (BC or BD) and triple (BCD) viral hepatitis in HIV-infected patients in Madrid, Spain. AIDS: 2005; 19 13 1361 1365
10. Konopnicki D, Mocroft A, de Wit S., et al. EuroSIDA Group Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS: 2005; 19 6 593 601
11. Rockstroh JK, Bhagani S, Benhamou Y., et al. EACS Executive Committee European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med: 2008; 9 2 82 88
12. Farci P. Delta hepatitis: an update. J Hepatol: 2003; 39 Suppl 1 S212 S219
13. Abbas Z, Jafri W, Raza S, Hepatitis D. Scenario in the Asia-Pacific region. World J Gastroenterol: 2010; 16 5 554 562
14. Viana S, Paraná R, Moreira RC, Compri AP, Macedo V. High prevalence of hepatitis B virus and hepatitis D virus in the western Brazilian Amazon. Am J Trop Med Hyg: 2005; 73 4 808 814
15. Cross TJ, Rizzi P, Horner M., et al. The increasing prevalence of hepatitis delta virus (HDV) infection in South London. J Med Virol: 2008; 80 2 277 282
16. Heidrich B, Deterding K, Tillmann HL, Raupach R, Manns MP, Wedemeyer H. Virological and clinical characteristics of delta hepatitis in Central Europe. J Viral Hepat: 2009; 16 12 883 894
17. Wedemeyer H, Heidrich B, Manns MP. Hepatitis D virus infectionnot a vanishing disease in Europe! Hepatology: 2007; 45 5 1331 1332, author reply 1332-1333
18. Ockenga J, Tillmann HL, Trautwein C, Stoll M, Manns MP, Schmidt RE. Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. J Hepatol: 1997; 27 1 18 24
19. Thio CL, Seaberg EC, Skolasky R Jr., et al. Multicenter AIDS Cohort Study. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet: 2002; 360 9349 1921 1926
20. Soriano V, Grint D, d'Arminio Monforte A., et al. Hepatitis delta in HIV-infected individuals in Europe. AIDS: 2011; 25 16 1987 1992
21. Gaeta GB, Precone DF, Cozzi-Lepri A, Cicconi P, D'Arminio Monforte A. Multiple viral infections. J Hepatol: 2006; 44 1, Suppl S108 S113
22. Martín-Carbonero L, Teixeira T, Poveda E., et al. Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues. AIDS: 2011; 25 1 73 79
23. Chang S-Y, Yang C-L, Ko W-S., et al. Molecular epidemiology of hepatitis D virus infection among injecting drug users with and without human immunodeficiency virus infection in Taiwan. J Clin Microbiol: 2011; 49 1083 1089
24. Taylor JM. Hepatitis delta virus. Virology: 2006; 344 1 71 76
25. Wang KS, Choo QL, Weiner AJ., et al. Structure, sequence and expression of the hepatitis delta (delta) viral genome. Nature: 1986; 323 6088 508 514
26. Kuo MY, Goldberg J, Coates L, Mason W, Gerin J, Taylor J. Molecular cloning of hepatitis delta virus RNA from an infected woodchuck liver: sequence, structure, and applications. J Virol: 1988; 62 6 1855 1861
27. Kos A, Dijkema R, Arnberg AC, van der Meide PH, Schellekens H. The hepatitis delta (delta) virus possesses a circular RNA. Nature: 1986; 323 6088 558 560
28. Fauquet C. Virus taxonomy: classification and nomenclature of viruses: eighth report of the International Committee on the Taxonomy of Viruses. San Diego, CA Academic Press: 2005
29. Cann A. Principles of molecular virology. San Diego, CA Academic Press: 2001
30. Abou-Jaoudé G, Molina S, Maurel P, Sureau C. Myristoylation signal transfer from the large to the middle or the small HBV envelope protein leads to a loss of HDV particles infectivity. Virology: 2007; 365 1 204 209
31. Engelke M, Mills K, Seitz S., et al. Characterization of a hepatitis B and hepatitis delta virus receptor binding site. Hepatology: 2006; 43 4 750 760
32. Abou-Jaoudé G, Sureau C. Entry of hepatitis delta virus requires the conserved cysteine residues of the hepatitis B virus envelope protein antigenic loop and is blocked by inhibitors of thiol-disulfide exchange. J Virol: 2007; 81 23 13057 13066
33. Lai MM. RNA replication without RNA-dependent RNA polymerase: surprises from hepatitis delta virus. J Virol: 2005; 79 13 7951 7958
34. Greco-Stewart VS, Miron P, Abrahem A, Pelchat M. The human RNA polymerase II interacts with the terminal stem-loop regions of the hepatitis delta virus RNA genome. Virology: 2007; 357 1 68 78
35. Li YJ, Macnaughton T, Gao L, Lai MM. RNA-templated replication of hepatitis delta virus: genomic and antigenomic RNAs associate with different nuclear bodies. J Virol: 2006; 80 13 6478 6486
36. Wong SK, Lazinski DW. Replicating hepatitis delta virus RNA is edited in the nucleus by the small form of ADAR1. Proc Natl Acad Sci U S A: 2002; 99 23 15118 15123
37. Chao M, Hsieh SY, Taylor J. Role of two forms of hepatitis delta virus antigen: evidence for a mechanism of self-limiting genome replication. J Virol: 1990; 64 10 5066 5069
38. Chang FL, Chen PJ, Tu SJ, Wang CJ, Chen DS. The large form of hepatitis delta antigen is crucial for assembly of hepatitis delta virus. Proc Natl Acad Sci U S A: 1991; 88 19 8490 8494
39. Casey J. RNA editing in hepatitis delta virus. Curr Top Microbiol Immunol: 2006; 307 67 89
40. Dény P. Hepatitis delta virus genetic variability: from genotypes I, II, III to eight major clades? In: Casey JL., ed. Hepatitis Delta Virus. Vol. 307. Heidelberg, Germany Springer: 2006; 151 171. Available at: http://www.springerlink.com/content/p34165241m171622/. Accessed February 4, 2012
41. Quintero A, Uzcátegui N, Loureiro CL., et al. Hepatitis delta virus genotypes I and III circulate associated with hepatitis B virus genotype F in Venezuela. J Med Virol: 2001; 64 3 356 359
42. Radjef N, Gordien E, Ivaniushina V., et al. Molecular phylogenetic analyses indicate a wide and ancient radiation of African hepatitis delta virus, suggesting a deltavirus genus of at least seven major clades. J Virol: 2004; 78 5 2537 2544
43. Le Gal F, Gault E, Ripault M-P., et al. Eighth major clade for hepatitis delta virus. Emerg Infect Dis: 2006; 12 9 1447 1450
44. Lyles C, Dorrucci M, Vlahov D., et al. Longitudinal human immunodeficiency virus type 1 load in the Italian seroconversion study: correlates and temporal trends of virus load. J Infect Dis: 1999; 180 1018 1024
45. Chen CJ, Yang HI, Su J., et al. REVEAL-HBV Study Group Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA: 2006; 295 1 65 73
46. Fattovich G, Giustina G, Christensen E., et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut: 2000; 46 3 420 426
47. Buti M, Homs M, Rodriguez-Frias F., et al. Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study. J Viral Hepat: 2011; 18 6 434 442
48. Niro GA, Smedile A, Ippolito AM., et al. Outcome of chronic delta hepatitis in Italy: a long-term cohort study. J Hepatol: 2010; 53 5 834 840
49. Hadziyannis SJ, Sherman M, Lieberman HM, Shafritz DA. Liver disease activity and hepatitis B virus replication in chronic delta antigen-positive hepatitis B virus carriers. Hepatology: 1985; 5 4 544 547
50. Chen PJ, Chen DS, Chen CR., et al. Delta infection in asymptomatic carriers of hepatitis B surface antigen: low prevalence of delta activity and effective suppression of hepatitis B virus replication. Hepatology: 1988; 8 5 1121 1124
51. Sagnelli E, Coppola N, Scolastico C., et al. Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. Hepatology: 2000; 32 5 1106 1110
52. Jardi R, Rodriguez F, Buti M., et al. Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology: 2001; 34 2 404 410
53. Zachou K, Yurdaydin C, Drebber U., et al. HIDT-1 Study Group Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. Liver Int: 2010; 30 3 430 437
54. Schaper M, Rodriguez-Frias F, Jardi R., et al. Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D. J Hepatol: 2010; 52 5 658 664
55. Wedemeyer H. Re-emerging interest in hepatitis delta: new insights into the dynamic interplay between HBV and HDV. J Hepatol: 2010; 52 5 627 629
56. Calle Serrano B, Heidrich B, Jaroszewicz J., et al. Dynamic fluctuation of virological markers during the natural course of hepatitis delta. J Hepatol: 2010; 52 S131 S132
57. Mathurin P, Thibault V, Kadidja K., et al. Replication status and histological features of patients with triple (B, C, D) and dual (B, C) hepatic infections. J Viral Hepat: 2000; 7 1 15 22
58. Raimondo G, Brunetto MR, Pontisso P., et al. Associazione Italiana Studio Fegato Cooperative Group Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology: 2006; 43 1 100 107
59. Pol S, Wesenfelder L, Dubois F., et al. Influence of immunodeficiency virus infection on hepatitis delta virus superinfection in chronic HBsAg carriers. J Viral Hepat: 1994; 1 131 137
60. Puoti M, Rossi S, Forleo MA., et al. Treatment of chronic hepatitis D with interferon alpha-2b in patients with human immunodeficiency virus infection. J Hepatol: 1998; 29 1 45 52
61. Boyd A, Lacombe K, Miailhes P., et al. Longitudinal evaluation of viral interactions in treated HIV-hepatitis B co-infected patients with additional hepatitis C and D virus. J Viral Hepat: 2010; 17 1 65 76
62. Williams V, Brichler S, Radjef N., et al. Hepatitis delta virus proteins repress hepatitis B virus enhancers and activate the alpha/beta interferon-inducible MxA gene. J Gen Virol: 2009; 90 Pt 11 2759 2767
63. Shih HH, Jeng K-S, Syu W-J., et al. Hepatitis B surface antigen levels and sequences of natural hepatitis B virus variants influence the assembly and secretion of hepatitis d virus. J Virol: 2008; 82 5 2250 2264
64. Pollicino T, Raffa G, Santantonio T., et al. Replicative and transcriptional activities of hepatitis B virus in patients coinfected with hepatitis B and hepatitis delta viruses. J Virol: 2011; 85 1 432 439
65. Aslan N, Yurdaydin C, Wiegand J., et al. Cytotoxic CD4 T cells in viral hepatitis. J Viral Hepat: 2006; 13 8 505 514
66. Grabowski J, Yurdaydìn C, Zachou K., et al. HIDIT-1 study group Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment. Liver Int: 2011; 31 9 1395 1405
67. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol: 2001; 19 65 91
68. Rizzetto M. Hepatitis D: virology, clinical and epidemiological aspects. Acta Gastroenterol Belg: 2000; 63 2 221 224
69. Yurdaydn C, Idilman R, Bozkaya H, Bozdayi AM. Natural history and treatment of chronic delta hepatitis. J Viral Hepat: 2010; 17 11 749 756
70. Tillmann HL, Hadem J, Leifeld L., et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat: 2006; 13 4 256 263
71. Mederacke I, Filmann N, Yurdaydin C., et al. Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation. J Hepatol: 2012; 56 1 115 122
72. Fattovich G, Boscaro S, Noventa F., et al. Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B. J Infect Dis: 1987; 155 5 931 935
73. Romeo R, Del Ninno E, Rumi M., et al. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology: 2009; 136 5 1629 1638
74. Eyster ME, Sanders JC, Battegay M, Di Bisceglie AM. Suppression of hepatitis C virus (HCV) replication by hepatitis D virus (HDV) in HIV-infected hemophiliacs with chronic hepatitis B and C. Dig Dis Sci: 1995; 40 7 1583 1588
75. Castellares C, Barreiro P, Martín-Carbonero L., et al. Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome. J Viral Hepat: 2008; 15 3 165 172
76. Sheng WH, Hung CC, Kao JH., et al. Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study. Clin Infect Dis: 2007; 44 7 988 995
77. Calle-Serrano B, Heidrich B, Homs M., et al. Development and evaluation of a baseline event-anticipation (BEA) score for hepatitis delta. Hepatology: 2011; 54 Suppl 1 360 455
78. Sulkowski M, Thomas D, Chaisson R, Moore R. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA: 2000; 283 74 80
79. Martínez E, Blanco JL, Arnaiz JA., et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS: 2001; 15 10 1261 1268
80. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology: 2002; 35 1 182 189
81. Soriano V, Puoti M, Peters M., et al. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS: 2008; 22 12 1399 1410
82. Mederacke I, Yurdaydin C, Dalekos GN., et al. Hep-Net/International Delta Hepatitis Study Group Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-α2a treatment. Antivir Ther: 2012; 17 2 305 312
83. Le Gal F, Gordien E, Affolabi D., et al. Quantification of hepatitis delta virus RNA in serum by consensus real-time PCR indicates different patterns of virological response to interferon therapy in chronically infected patients. J Clin Microbiol: 2005; 43 5 2363 2369
84. Mederacke I, Bremer B, Heidrich B., et al. Establishment of a novel quantitative hepatitis D virus (HDV) RNA assay using the Cobas TaqMan platform to study HDV RNA kinetics. J Clin Microbiol: 2010; 48 6 2022 2029
85. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol: 2009; 50 2 227 242
86. Wedemeyer H, Yurdaydìn C, Dalekos GN., et al. HIDIT Study Group Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med: 2011; 364 4 322 331
87. Lau DT, Kleiner DE, Park Y, Di Bisceglie AM, Hoofnagle JH. Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy. Gastroenterology: 1999; 117 5 1229 1233
88. Di Martino V, Thevenot T, Colin JF., et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology: 2002; 123 6 1812 1822
89. Garripoli A, Di Marco V, Cozzolongo R., et al. Ribavirin treatment for chronic hepatitis D: a pilot study. Liver: 1994; 14 3 154 157
90. Yurdaydin C, Bozkaya H, Gürel S., et al. Famciclovir treatment of chronic delta hepatitis. J Hepatol: 2002; 37 2 266 271
91. Yurdaydn C, Bozkaya H, Önder FO., et al. Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon. J Viral Hepat: 2008; 15 4 314 321
92. Sheldon J, Ramos B, Toro C., et al. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients? Antivir Ther: 2008; 13 1 97 102
93. Matthews GV, Bartholomeusz A, Locarnini S., et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS: 2006; 20 6 863 870
94. Lok AS, Lai C-L, Leung N., et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology: 2003; 125 6 1714 1722
95. Vietheer PT, Netter HJ, Sozzi T, Bartholomeusz A. Failure of the lamivudine-resistant rtM204I hepatitis B virus mutants to efficiently support hepatitis delta virus secretion. J Virol: 2005; 79 10 6570 6573
96. Lincoln D, Petoumenos K, Dore GJ.; Australian HIV Observational Database. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med: 2003; 4 3 241 249
97. Proof-of-Concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV) - ClinicalTrials.gov. Available at: http://clinicaltrials. gov/ct2/show/NCT01316185?term=hepatitis+delta&recr=Open&no-unk= Y&cond=hepatitis+D&rank=2. Accessed March 10, 2012
98. Hepatitis Delta International Network. Available at: http://hepatitis- delta.org/hdin-database/. Accessed March 10, 2012